2018
Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside
Chae WJ, Bothwell ALM. Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Frontiers In Immunology 2018, 9: 303. PMID: 29503652, PMCID: PMC5820299, DOI: 10.3389/fimmu.2018.00303.Peer-Reviewed Original ResearchConceptsRegulatory T cellsInflammatory diseasesT cellsImmune responseEffective antitumor immune responseTherapeutic potentialT cell receptor specificityDysfunction of TregsField of TregsAberrant immune responseAdaptive immune cellsAntitumor immune responseInherent genetic defectsRecognition of antigenTreg functionChronic inflammationImmune cellsTregsImmune reactionsRecipients resultsTherapeutic approachesBasic research findingsOrgan donorsSuppressive functionImmune system
2016
The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes
Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 2016, 120: 11-19. PMID: 26979921, PMCID: PMC5820030, DOI: 10.1016/j.neuropharm.2016.03.021.Peer-Reviewed Original ResearchConceptsCNS drug discoveryClinical failure rateDisease-modifying treatmentsEffects of drugsMajor neurodegenerative disordersMajor neurodegenerative diseasesNon-CNS drugsFuture CNSCNS diseaseFailure rateCNS disordersCNS targetsBasic research findingsField of neuropharmacologyCNS drugsClinical developmentNeuronal functionNeurological disordersNeurodegenerative disordersNeurodegenerative diseasesHigh failure rateDrug discoveryCNSNew drugsDrugs
2015
Current Research and Opportunities to Address Environmental Asbestos Exposures
Carlin D, Larson T, Pfau J, Gavett S, Shukla A, Miller A, Hines R. Current Research and Opportunities to Address Environmental Asbestos Exposures. Environmental Health Perspectives 2015, 123: a194-a197. PMID: 26230287, PMCID: PMC4529018, DOI: 10.1289/ehp.1409662.Peer-Reviewed Original ResearchConceptsEnvironmental asbestos exposureAsbestos exposureAsbestos-related diseasesHealth effectsRisk factorsOccupational exposureBasic research findingsDisease RegistryEnvironmental Health SciencesToxicological findingsTumor developmentSociety of ToxicologyHazardous exposuresPotential health risksDose metricsNational InstituteSusceptible populationPublic healthHigh rateAsbestosHealth risksDiseaseExposureProper dose metricToxicity
2010
Awake Rat Pharmacological Magnetic Resonance Imaging as a Translational Pharmacodynamic Biomarker: Metabotropic Glutamate 2/3 Agonist Modulation of Ketamine-Induced Blood Oxygenation Level Dependence Signals
Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, Day M. Awake Rat Pharmacological Magnetic Resonance Imaging as a Translational Pharmacodynamic Biomarker: Metabotropic Glutamate 2/3 Agonist Modulation of Ketamine-Induced Blood Oxygenation Level Dependence Signals. Journal Of Pharmacology And Experimental Therapeutics 2010, 336: 709-715. PMID: 21172908, DOI: 10.1124/jpet.110.173880.Peer-Reviewed Original ResearchConceptsPharmacological magnetic resonance imagingMagnetic resonance imagingBrain activationPeriaqueductal grayMetabotropic Glutamate 2/3 Receptor AgonistN-methyl-D-aspartate receptor antagonistResonance imagingBOLD signalEarly clinical trialsNegative BOLD signalsNovel experimental therapeuticsPositive BOLD signalRegion-specific mannerPhMRI studiesReceptor antagonistPharmacodynamic biomarkersReceptor agonistSubanesthetic doseAgonist modulationClinical trialsAwake ratsHippocampal regionBasic research findingsDose selectionAnesthetized animals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply